---
title: "Pfizer: Challenges Loom Amid Overvaluation"
date: "2025-02-10 17:39:03"
summary: "jetcityimage  Introduction Pfizer Inc.'s (NYSE:PFE) stock price continued stagnating over the last three months, which reinforces my cautious stance I discussed in November. Despite being one of a few companies that helped to save the"
categories:
  - "seekalpha_articles"
lang:
  - "en"
translations:
  - "en"
tags:
  - "seekalpha_articles"
menu: ""
thumbnail: "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2149808923/image_2149808923.jpg"
lead: ""
comments: false
authorbox: false
pager: true
toc: false
mathjax: false
sidebar: "right"
widgets:
  - "search"
  - "recent"
  - "taglist"
---

![Pfizer site manufacturing heparin active pharmaceutical ingredient. Pfizer is a pharmaceutical biotechnology corporation.](https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2149808923/image_2149808923.jpg?io=getty-c-w750) 



jetcityimage





Introduction
------------

**Pfizer Inc.****'s** (NYSE:[PFE](https://seekingalpha.com/symbol/PFE "Pfizer Inc.")) stock price continued stagnating over the last three months, which reinforces my cautious stance I discussed [in November](https://seekingalpha.com/article/4736043-pfizer-do-not-be-fooled-by-6-percent-plus-dividend-yield). Despite being one of a few companies that helped to save the

[seekalpha_articles](https://seekingalpha.com/article/4756618-pfizer-challenges-loom-amid-overvaluation)
